The study aims to establish a nomogram to predict advanced pancreatic carcinoma patients’ overall survival (OS), incorporating albumin combined with systemic immune-inflammation index (A-SII) score and clinical characteristics. The gene discussed is ALB; the disease is exocrine pancreatic carcinoma.